文献速递神经肿瘤神经重症

YBX1与YBX3作为增强胶质瘤免疫检查点阻断应答的新靶点

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.
PubMed 文献 · Neuro Oncol · 2026-01-01

该研究探讨胶质母细胞瘤中CHK2-YBX1&YBX3调控轴驱动的免疫逃逸机制。通过蛋白互作、基因敲除、转录组与表观遗传分析及单细胞空间转录组,发现三者相互正调控,靶向YBX1的药物可降解该复合体并增强抗原递呈与CD8⁺T细胞增殖,联合ICB显著改善临床前模型生存。

要点

  • CHK2、YBX1、YBX3相互正调控,敲除任一基因均解除促炎基因抑制。
  • 靶向YBX1的药物可降解CHK2-YBX1&YBX3复合体并增强抗原递呈。
  • 靶向该复合体联合ICB显著改善临床前胶质瘤模型生存。

核心结论

  • 胶质瘤内在的CHK2-YBX1&YBX3调控轴驱动免疫抑制,靶向该轴可增强ICB应答。

研究设计与样本

  • 采用免疫沉淀联合质谱及磷酸化蛋白质组学分析蛋白互作。
  • 在人及小鼠胶质瘤细胞中构建CHEK2、YBX1、YBX3单基因敲除。
  • 通过bulk RNA测序与ChIP-seq表征转录组及表观遗传改变。
  • 采用单细胞RNA测序与空间转录组分析人GBM肿瘤相关表型。
  • 开展体内生存研究评估CHK2-YBX1&YBX3降解联合ICB的治疗潜力。

主要发现

  • CHK2、YBX1、YBX3相互正调控,敲除任一基因均导致促炎基因表达去抑制。
  • 靶向YBX1的药物抑制导致CHK2-YBX1&YBX3复合体降解,伴抗原递呈增强及抗原特异性CD8⁺T细胞增殖。
  • 靶向CHK2-YBX1&YBX3复合体联合ICB显著改善临床前胶质瘤模型生存。

临床怎么用

  • 靶向YBX1的药物联合ICB可能作为增强胶质瘤免疫治疗应答的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) exhibits profound resistance to CD8⁺ T cell-mediated killing, yet the tumor-intrinsic mechanisms driving this immune evasion remain poorly defined. Our earlier study revealed Checkpoint Kinase 2 (Chek2) as the driver of CD8+ T cell resistance. This study investigates the immunomodulatory program exerted by the CHK2-YBX1&YBX3 regulatory hub. METHODS: Protein-protein interactions were investigated through immunoprecipitation (IP) followed by mass spectrometry (MS) and phosphoproteomics. Single gene knockout of CHEK2, Y-box-binding protein 1 (YBX1), and Y-box-binding protein 3 (YBX3) were generated in human and mouse glioma cells. Transcriptomic and epigenetic alterations were characterized by bulk RNA sequencing and chromatin immunoprecipitation sequencing (ChIP-seq). Single-cell RNA sequencing and spatial transcriptomics analysis were performed to evaluate CHK2-YBX1&YBX3 related phenotype in human GBM tumors. In vivo survival studies were conducted to assess the therapeutic potential of CHK2-YBX1&YBX3 degradation and immune checkpoint blockade (ICB). RESULTS: CHK2, YBX1, and YBX3 exhibited reciprocal positive regulation and depletion of any of these genes resulted in derepression of pro-inflammatory gene expression. Pharmacological inhibition with the drug targeting YBX1 led to degradation of the CHK2-YBX1&YBX3 hub accompanied by enhanced antigen presentation and antigen-specific CD8⁺ T cell proliferation. Combination therapy targeting CHK2-YBX1&YBX3 hub and ICB significantly improved survival in preclinical glioma models. CONCLUSIONS: These findings define a novel glioma-intrinsic immunosuppressive program and proposes targeting the CHK2-YBX1&YBX3 hub to potentiate response to ICB in glioma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ali H, Zhou N, Chen L, et al. YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas. Neuro Oncol. 2026. PMID: 41025501. doi:10.1093/neuonc/noaf227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。